
Valeant company group chairman and executive vice president resigns
pharmafile | March 3, 2016 | Appointment | Medical Communications, Sales and Marketing | Valeant, appointed, resignation
In an already troubled week for Valeant Pharmaceuticals, the company has now announced that its group chairman and executive vice president, Deb Jorn, has resigned her position. She was responsible for the Canada-based firm’s major US dermatology and gastrointestinal therapeutic areas.
Estimated to represent half of Valeant’s forecasted 2016 US revenues, these two businesses are vital to the company’s performance. Its dermatology business, of course, is under severe scrutiny following the Philidor scandal.
A management shake-up has followed with Eric Abramson, vice president dermatology and immunology marketing, appointed general manager of the US dermatology business. Dr Ari Kellen, meanwhile, executive vice president and company group chairman will be in control of Valeant’s gastrointestinal business.
A statement from Valeant has indicated that it is their understanding that Jorn left the role for personal reasons and that her departure is “not the result of an action taken by the Ad Hoc Committee of the Board of Directors.”
Related Content

FDA rejects Valeant plaque psoriasis lotion over pharmacokinetic concerns
Beleaguered pharma firm Valeant has come up against another bump in the road as its …

Top Ten most popular articles on Pharmafile.com this week
It’s been a week in which one of the largest pharmaceutical takeovers in history took …

Valeant seeks clean slate with rebrand, new company name
In the latest attempt to reverse its ailing fortunes and distance itself from its polluted …






